MaxCyte, Kamau Therapeutics Partner for Flow Electroporation Technology-February 2024-www.financetom.com

MaxCyte, Kamau Therapeutics Partner for Flow Electroporation Technology

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

MaxCyte, Kamau Therapeutics Partner for Flow Electroporation Technology

Sep 16, 2024 1:42 AM

04:19 AM EDT, 09/16/2024 (MT Newswires) -- MaxCyte ( MXCT ) said Sunday that it had entered into a strategic platform license agreement with Kamau Therapeutics.

Under the agreement, Kamau obtains non-exclusive research, clinical, and commercial rights to use MaxCyte's ( MXCT ) flow electroporation technology and ExPERTTM platform.

The company said it is entitled to receive annual licensing fees and program-related revenue in return.

Price: 4.0000, Change: -0.03, Percent Change: -0.74

Previous page： Dave Insider Sold Shares Worth $2,925,322, According to a Recent SEC Filing Next page： Axsome Therapeutics Insider Sold Shares Worth $1,141,514, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Dave Insider Sold Shares Worth $2,925,322, According to a Recent SEC Filing

Sep 8, 2025

03:23 AM EDT, 09/08/2025 (MT Newswires) -- Yadin Rozov, Director, on September 04, 2025, sold 14,660 shares in Dave ( DAVE ) for $2,925,322. Following the Form 4 filing with the SEC, Rozov has control over a total of 82,123 Class A common shares of the company, with 79,923 shares held directly and 2,200 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1841408/000095017025113312/xslF345X05/ownership.xml ...

Axsome Therapeutics Insider Sold Shares Worth $1,141,514, According to a Recent SEC Filing

Sep 8, 2025

03:21 AM EDT, 09/08/2025 (MT Newswires) -- Mark E Saad, Director, on September 05, 2025, sold 9,127 shares in Axsome Therapeutics ( AXSM ) for $1,141,514. Following the Form 4 filing with the SEC, Saad has control over a total of 10,302 common shares of the company, with 10,002 shares held directly and 300 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1579428/000095017025113311/xslF345X05/ownership.xml ...

Volkswagen CEO: tariffs have cost group billions so far

Sep 8, 2025

MUNICH (Reuters) -U.S. tariffs have cost Volkswagen, Europe's largest carmaker, billions of euros so far, its chief executive said on Monday, adding that its key brand Porsche was being squeezed in a sandwich of duties and a weak Chinese market. Up to now, it's several billion euros on our balance sheet that this situation costs this year, Oliver Blume told...

Dave Insider Sold Shares Worth $1,506,894, According to a Recent SEC Filing

Sep 8, 2025

03:20 AM EDT, 09/08/2025 (MT Newswires) -- Jason Wilk, Director, Chief Executive Officer, on September 04, 2025, sold 7,557 shares in Dave ( DAVE ) for $1,506,894. Following the Form 4 filing with the SEC, Wilk has control over a total of 265,736 Class A common shares of the company, with 217,854 shares held directly and 47,882 controlled indirectly. SEC...